What's the Problem?

Nanomedicines (NMDs) are nano-scale vehicles that contain drugs inside. They protect these drugs from getting destroyed inside the body, allowing them to act selectively on diseased cells and avoiding secondary side effects on healthy cells. Such innovations improve patient’s life quality by reducing their treatments’ heavy side effects and by allowing to increase the dose amount, achieving more effective therapies. However, after 40 years of intense research in NMDs, only 50 products worldwide have reached patients. Their main obstacle is that they are complex systems and highly dependent on the manufacturing process. The traditional technology used to produce NMDs works in turbulent flows, with uncontrolled synthesis and with high consumption of reagents and time. This method is far from optimal for the pharmaceutical industry requirements due to its batch-to-batch variations, long and inefficient processes and difficulties both in scalability and optimization.

How are they Solving it?

Plamic uses microfluidics to overcome the limitations of traditional methods for nanomedicines’ R&D and production. In a chip that fits in the palm of a hand, microchannels are designed small enough to obtain a low Reynolds number of the fluids within them, achieving a laminar regime that allows a precise control of the fluids’ movement. Plamic team is expert both in microfluidics and nanomedicines, this combination is key to obtain unique chip designs that result in also unique nanomedicines formulations. Plamic is getting reproducible nanomedicines with pharmaceutical quality, and at the same time, accessibility to scale its production process in order to supply the pharmaceutical industry’s large demands.

Go to their website

Next Startup

Stämm

Go back to portfolio